Last reviewed · How we verify
NCT07320326: ASPIRE
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
trial testing Elranatamab in TCE-RRMM in 159 participants. Not yet recruiting.
18 July 2028
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 159 |
| Start date | 30 December 2025 |
| Primary completion | 18 July 2028 |
| Estimated completion | 18 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Elranatamab (elranatamab) — full drug profile →
Conditions studied
- TCE-RRMM — all drugs for TCE-RRMM →
Sponsor
Peking University People's Hospital
Who can join
18 and older, any sex, with TCE-RRMM. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07320326
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Elranatamab
Trials testing the same drug.
- NCT07382739 — A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Mye · Phase 2 · recruiting
- NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
- NCT06997081 — ERd Combination Treatment in Newly Diagnosed Multiple Myeloma · Phase 2 · recruiting
- NCT06581848 — Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). · active not recruiting
- NCT06931704 — Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in · Phase 2 · not yet recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07320326 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07320326.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing